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A B S T R A C T
Alzheimer's disease (AD) is a neurodegenerative disorder which accounts for 60–70% of the 50 million world-
wide cases of dementia and is characterised by cognitive impairments, many of which have long been associated
with dysfunction of the cholinergic system. Although the M1 muscarinic acetylcholine receptor (mAChR) is
considered a promising drug target for AD, ligands targeting this receptor have so far been unsuccessful in
clinical trials. As modulatory receptors to cholinergic transmission, the endocannabinoid system may be a
promising drug target to allow fine tuning of the cholinergic system. Furthermore, disease-related changes have
been found in the endocannabinoid system during AD progression and indeed targeting the endocannabinoid
system at specific disease stages alleviates cognitive symptoms in numerous mouse models of AD. Here we
review the role of the endocannabinoid system in AD, and its crosstalk with mAChRs as a potential drug target
for cholinergic dysfunction.
1. Introduction
50 million people worldwide currently live with dementia and, with
an increasingly ageing population, this figure is expected to rise
to> 150 million worldwide by 2050, becoming the second leading
cause of morbidity in the developed world after cancer [1]. The current
estimated financial cost of dementia in the United Kingdom is £26.3
billion per year. Although the National Health Service and social ser-
vices cover approximately £14.6 billion of this, some £17.4 billion –
two thirds of the total cost – is covered by patients and their families
[2]. Of the 50 million worldwide cases of dementia, 60–70% of these
are cases of Alzheimer's disease (AD).
AD is predominantly associated with memory loss, but symptoms
also include agitation, psychosis, depression, apathy, disinhibition,
anxiety and sleep disorders [3]. The pathological hallmarks of Alzhei-
mer's disease are brain atrophy and neuroinflammation, which are
thought to be largely provoked by the deposition of amyloid-beta (Aβ)
peptide into neuritic plaques and neurofibrillary tangles of tau protein
[4,5] although the role of these is still not entirely understood. How-
ever, the cholinergic system has long been implicated in the patho-
physiology of AD, as a plethora of cholinergic pathways serving roles in
conscious awareness, attention and working memory have been con-
sistently found to be damaged in the brains of those with advanced AD
[6,7]. Furthermore, cholinergic transmission is reduced in several key
brain regions in AD including the hippocampus, which is associated
with memory formation [8,9]. This has resulted in the development of
the ‘cholinergic hypothesis’, which postulates that a loss of cholinergic
function in the central nervous system (CNS) significantly contributes
to the cognitive decline associated with AD [10] and, as such, re-
presents a druggable target for AD. Consequently, current AD treatment
strategies focus on improving acetylcholine (ACh) availability. Indeed,
currently available drugs for AD – acetylcholinesterase (AChE) in-
hibitors – alleviate symptoms by increasing ACh availability in the sy-
naptic cleft of affected brain regions. By augmenting synaptic ACh
concentration, AD symptoms can be relieved and the rate of cognitive
decline can be slowed. Although improving ACh availability clearly
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shows improvements in AD symptoms, AChE inhibitors are nonselective
in nature, which renders a myriad of dose-related adverse effects – such
as gastrointestinal disturbances and bronchoconstriction [8]. Further-
more, only 30–40% of patients are responsive to AChE inhibitors [11].
Therefore, the clinical usefulness of AChE inhibitors is limited.
1.1. Acetylcholine receptors in Alzheimer's disease
Current research in AD drug discovery therefore strives to find al-
ternative routes to target the dysregulation of cholinergic signalling.
Both nicotinic and muscarinic acetylcholine receptors (nAChRs and
mAChRs, respectively) have been implicated in AD. Among the fast-
acting, channel-forming nAChRs, the α7 nAChR is of particular re-
levance to AD pathology, given its high expression levels in the hip-
pocampus and physiological role in the enhancement of learning and
memory [12,13]. Furthermore, Aβ has been shown to enrich in regions
abundant in α7 nAChR and elevated levels of the α7 nAChR-Aβ com-
plex are thought to disrupt normal cholinergic signalling, including that
involved in synaptic plasticity, ultimately resulting in cognitive dys-
function [12,14,15]. Indeed, administration of α7 nAChR agonists
AZD0328 and SSR180711 has shown improved cognition in rodents
[16,17], and therefore the α7 nAChR undoubtedly represents a pro-
mising drug target for AD treatment. However, the role of α7 nAChR in
AD lies beyond the scope of this review, and is more extensively dis-
cussed elsewhere.
The mAChRs – of which five subtypes (M1-M5) exist – regulate nu-
merous functions in both the central nervous system and the periphery
[18]. mAChRs belong to the Class A G protein coupled receptor (GPCR)
superfamily, and are thus large, membrane-bound proteins consisting of
7 transmembrane domains. mAChRs contain an orthosteric binding site,
to which endogenous acetylcholine binds, and intracellular regions
where interactions with G proteins take place. Upon agonist binding,
the recruitment of G proteins initiates downstream signalling cascades;
M1, M3 and M5 mAChRs are coupled to Gαq/11 proteins, while M2 and
M4 mAChRs are coupled to Gαi/O. The recruitment of Gαq/11 typically
initiates coupling to phospholipase C (PLC), subsequently promoting
the release of intracellular calcium ([Ca2+]i). The release of [Ca2+]i is
generally excitatory in nature; for example by facilitating the propa-
gation of neuronal excitation through ion channel opening and the re-
lease of neurotransmitters from intracellular vesicles. Meanwhile, Gαi
recruitment is inhibitory in nature; agonist binding to M2 and M4
mAChRs results in the downregulation of adenylyl cyclase activity and
reduced levels of cyclic adenosine monophosphate (cAMP), while de-
creasing the activity of voltage-activated Ca2+ channels, and increasing
coupling to mitogen-activated protein kinase (MAPK) pathway [18,19].
Of the five mAChR subtypes, M1 mAChR is the most abundantly
expressed in the brain [20]. Of particular note, M1 mAChR has long
been implicated in learning and memory in the hippocampus. Recent
studies have indicated that M1 mAChR expression and signalling is
maintained in terminal AD patients [21] suggesting that drugs targeting
this receptor subtype will be efficacious even in late disease. Not all
studies however support this notion but rather have reported a down-
regulation of M1 mAChR expression of approximately 50% in AD [22].
Encouragingly, activation of this receptor can have pro-cognitive ef-
fects, as illustrated by xanomeline, an M1/M4-preferring agonist, which
elicited significant cognitive and behavioural improvements in AD pa-
tients [23]. M1 mAChR is thus considered a promising target for the
treatment of AD. However, despite such initially promising results,
xanomeline ultimately failed in clinical trials due largely to off-target
peripheral gastrointestinal and cardiovascular adverse effects thought
to be mediated by M2 and M3 mAChR activation [24]. Indeed, the
highly conserved nature of the orthosteric site across all 5 mAChR
subtypes has made generating selective muscarinic ligands a challenge
that has seriously hampered drug discovery efforts [25]. Efforts to
generate selective muscarinic ligands have recently focused on allos-
teric compounds which target sites which are spatially distinct to the
orthosteric binding sites. Allosteric molecules that enhance the activity
of the natural ligand acetylcholine – so called positive allosteric mod-
ulators (PAMs) – have shown promise by improving both cognitive
symptoms and survival in mouse cholinergic-deficit models [26] and in
murine prion neurodegeneration [27].
Collectively these studies have provided evidence that the M1
mAChR is a promising molecular target that can not only improve
deficits in learning and memory in neurodegenerative disease but also
slow the disease progression. This conclusion has encouraged numerous
drug discovery efforts that have resulted in clinical studies of both or-
thosteric [28] as well as allosteric/bitopic ligands [29] which have
provided evidence of clinical efficacy, supporting the M1 mAChR as a
target in AD.
2. The endocannabinoid system
The cannabinoid system encompasses endogenous cannabinoids
(endocannabinoids), plant-derived cannabinoids (phytocannabinoids)
and their target receptors, all of which are Class A GPCRs. Numerous
synthetic cannabinoids are now available for research purposes
(Table 1). Cannabinoids have received particular public attention in
recent years, with the cannabis-based compound Sativex and the syn-
thetic cannabinoid Nabilone having been legalised for medicinal pur-
poses in the UK since late 2018. However, their prescription under the
Table 1
Summary of key endocannabinoids, phytocannabinoids and synthetic cannabinoids and their activity at endocannabinoid receptors. The pharmacology of the
numerous cannabinoids discovered and synthetic cannabinoids now available are extensively reviewed elsewhere (e.g. [67]).
Cannabinoid CB1 activity CB2 activity GPR55 activity
Endogenous Cannabinoids 2-arachidonoyl glycerol (2-AG) Agonist Agonist Agonist
N-arachidonoylethanolamine (anandamide; AEA) Agonist Agonist Agonist
Lysophosphatidyl inositol (LPI) Agonist
N-arachidonyl glycine (NAGly) Agonist
Phytocannabinoids Δ9-tetrahydrocannabinol (Δ9-THC1; THC) Partial Agonist Partial Agonist Agonist
Cannabidiol (CBD) Negative Allosteric Modulator Partial Agonist Antagonist
Synthetic Cannabinoids WIN55,212–2 Agonist Agonist
Arachidonyl-2′-chloroethylamide (ACEA) Agonist, potent and selective
Arachidonylcyclopropylamide (ACPA) Agonist, potent and selective
SR141716a (Rimonabant) Antagonist Antagonist
AM251 Inverse agonist Agonist
JWH-133 Agonist
JWH-015 Agonist Agonist
AM630 Antagonist
SR144528 Antagonist
ML184 Agonist
ML193 Antagonist
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NHS remains restricted.
It was initially believed that the endocannabinoid system only
contained two target receptors – CB1 and CB2. However, the recently
deorphanised GPR55 is now also considered a cannabinoid receptor,
given that – in addition to its endogenous activation by lysopho-
sphatidyl inositol (LPI) and N-arachidonyl glycine (NAGly) [30,31] – it
is activated by a breadth of endo-, phyto- and synthetic cannabinoids
[32–37]. Interestingly, GPR55 has fairly low sequence homology with
both CB1 (13.5%) and CB2 (14.4%) [36,38], and lacks the classical
cannabinoid binding pocket expressed by CB1 and CB2 [39], meaning
that it is somewhat of an atypical cannabinoid receptor. Collectively,
the endogenous ligands, their receptors, and the enzymes which break
them down comprise the endocannabinoid system.
2.1. Endogenous endocannabinoid ligands and their synthesis
The primary endocannabinoids are 2-arachidonoyl glycerol (2-AG)
and N-arachidonoylethanolamine (anandamide; AEA), which both ac-
tivate CB1, CB2 and GPR55 with similar efficacy and nanomolar po-
tency [36]. Within the CNS, 2-AG is formed postsynaptically from
phosphatidylinositol through the actions of PLC and diacylglycerol
(DAG) lipase. Likewise, AEA is produced postsynaptically, but in this
case is a downstream product of both phospholipase A2 and PLC [15].
Interestingly, LPI – the primary endogenous ligand for GPR55 – is
thought to lie downstream of PLC and DAG formation, meaning that
both LPI and 2-AG arise from the same second messenger pathway
[32,40]. Therefore, the activation of cells via receptors coupled to PLC
and PLA2 pathways results in the formation of endocannabinoids. En-
docannabinoids are retrograde neurotransmitters; within the CNS, they
are released from the postsynaptic neuron into the synaptic cleft and
signal in a retrograde manner to endocannabinoid receptors expressed
on presynaptic neurons. In this way, endocannabinoid receptors behave
as modulators of presynaptic neurotransmitter release.
2-AG and AEA are broken down by monoacylglycerol lipase (MAGL)
and fatty acid amide hydrolase (FAAH) respectively [41]. These
breakdown enzymes, much like AChE as discussed above, may be ex-
ploitable as drug targets in diseases which may benefit from targeting
strategies designed to upregulate the endocannabinoid system. This will
be discussed in greater detail below.
2.2. Endogenous cannabimimetics
AEA is one of many endogenous N-acylethanolamine fatty acid
amides which are produced concomitantly with AEA, and indeed di-
homo-γ-lonolenic acid, mead acid, and adrenic acid are also capable of
binding cannabinoid receptors [42,43]. However, the most abundantly
produced N-acylethanolamines include palmitoylethanolamide and
stearoylethanolamide, which do not bind cannabinoid receptors. In-
stead, a role for palmitoylethanolamide in anti-inflammatory, an-
algesic, anti-epileptic and neuroprotective functions is thought to be
mediated at least in part by the peroxisome proliferator-activated re-
ceptor α (PPARα) [44,45]. Indeed, palmitoylethanolamide has been
suggested as therapeutically useful across a breadth of pathologies,
including neurodegeneration (reviewed in [46]). Meanwhile, N-stear-
oylethanolamide treatment prevented the loss of α7 nAChRs and the
accumulation of pathogenic Aβ bound to α7 nAChRs in the brains of
mice treated with bacterial lipopolysaccharide, which otherwise exhibit
α7 nAChR loss and pathogenic Aβ binding to α7 nAChR accumulation
[47]. Furthermore, N-stearoylethanolamide improved episodic memory
in these mice, indicating treatment with N-stearoylethanolamide de-
monstrates a therapeutic potential for the prevention of cognitive
dysfunction caused by neuroinflammation such as that seen in AD.
Many N-acylethanolamines concomitantly produced with AEA –
including pamitoylethanolamide and N-stearoylethanolamide, as dis-
cussed above – are more abundant in most animal tissues than AEA. It
has therefore been recently speculated that the release of such N-
acylethanolamines could be the primary downstream products of the
pathways producing AEA (reviewed in [48]). The potential therapeutic
benefits of the N-acylethanolamines for neurodegenerative diseases, as
briefly outlined above, are of importance when considering targeting
the endocannabinoid system. However, more in-depth research is re-
quired in order to fully elucidate the druggable potential of the can-
nabimimetic N-acylethanolamines.
2.3. Phytocannabinoids
Phytocannabinoids have been used for recreational and therapeutic
purposes for thousands of years [49], but have been of particular public
interest in recent years given numerous emerging reports of the ther-
apeutic potential in otherwise uncontrolled epilepsy, pain disorders,
emesis and multiple sclerosis-related spasticity. To date, over 100
phytocannabinoids falling into eleven different chemical classes have
been identified. All phytocannabinoid classes and their purported ac-
tions are reviewed extensively elsewhere [49,50]. Of importance,
however, are the Δ9-tetrahydrocannabinol (Δ9-THC1; THC) and canna-
bidiol (CBD) classes, which are typically the two most abundant phy-
tocannabinoids in Cannabis sativa respectively [50,51]. While THC is
the main psychoactive component of cannabis, CBD retains the an-
algesic and anti-inflammatory properties of cannabis while being de-
void of psychotropic effects.
THC is a partial agonist at both CB1 and CB2, with similar binding
affinity at both receptors in AtT-20 [52] and Chinese Hamster Ovary
(CHO) [53] cell lines. However, a modest reduction in THC potency for
CB2 in comparison to CB1 was seen in the inhibition of forskolin-sti-
mulated cAMP accumulation [52]. The characteristics of THC at the
CB1 receptor have been paralleled to those of anandamide in terms of
affinity, partial agonism and lower efficacy at CB2 in vitro [54].
Meanwhile, THC acts as a full agonist at GPR55, with nanomolar po-
tency in a GTPγS assay [36].
In contrast to THC, CBD appears to act as a negative allosteric
modulator (NAM) at the CB1 receptor. The affinity for CBD is reportedly
very low, with a meta-analysis indicating a Ki of 3245 nM for CBD at the
CB1 orthosteric site [55]. However, submicromolar concentrations of
CBD were sufficient to inhibit internalisation of endogenously ex-
pressed CB1 in the STHdhQ7/Q7 cell culture model of striatal medium
spiny projection neurons [56], suggesting that CBD is capable of af-
fecting CB1 signalling at concentrations lower than those required for
orthosteric binding. Indeed, the affinity of CBD to the allosteric binding
site (KB) on CB1 has been found to be between 270 and 352 nM in
HEK293 cells, and between 278 and 333 nM in STHdhQ7/Q7 cells [57]. A
degree of functional selectivity was seen in STHdhQ7/Q7 (but not
HEK293) cells, but importantly CBD reduced the potency and efficacy
of both THC and 2-AG in both of these cell lines [57,51]. Meanwhile at
the CB2 receptor, CBD is an orthosteric partial agonist, capable of
competing with the synthetic CB2 receptor agonist SR144528 [51].
Finally, CBD is a competitive antagonist of GPR55 [36,51], and is also
capable in vitro of anandamide uptake inhibition, thus increasing en-
docannabinoid availability [58,59]. Indeed, this may well explain some
of the reported therapeutic effects of CBD, given that the uptake me-
chanisms of anandamide and 2-AG are potential therapeutic targets, as
discussed in detail below.
In addition to their activity at their putative endocannabinoid re-
ceptors, both THC and CBD modulate the activity of numerous addi-
tional cellular effectors. For example, THC has been found to inhibit
5HT3A-induced currents in HEK293 cells and cultured rat trigeminal
ganglion neurons [60,61], while potentiating positive allosteric mod-
ulatory effects at TRPA1 [62] and TRPV2 [63]. Meanwhile, CBD also
modulates 5HT1A [64], GPR55 [36], μ- and δ-opioid receptors [65],
TRPV1 channels [58], and PPARγ [66]. Therefore, when considering
the therapeutic potential of cannabinoids, such off-target activity must
be borne in mind. Given that the proportion of each chemical class –
dependent on numerous aspects such as the strain of the plant, growing
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conditions, and processing methods – varies enormously, this can pro-
duce substantial pharmacological variations in Cannabis sativa. It is thus
crucial to fully understand the pharmacological properties of each of
the phytocannabinoids to exploit their potential, and the potential of
the endocannabinoid system as a druggable target.
2.4. Synthetic cannabinoids
The discovery of the endocannabinoid system was soon followed by
the production of numerous synthetic cannabinoid compounds in a bid
to advance research and understanding around the endocannabinoid
system and its potential for therapeutic exploitation. A plethora of such
synthetic compounds now exists, and are extensively reviewed else-
where (e.g. [67]). A summary of key synthetic compounds now widely
used in research is provided in Table 1.
The highly potent, yet nonselective, CB agonist WIN55,212-2
(WIN55212) was first synthesised in 1992 [68]. This analogue of pra-
vadoline exerts full agonism at both the CB1 [52,53,69] and CB2 re-
ceptors [70]. However, it is noteworthy that WIN55212 has higher
affinity and efficacy at CB2 than CB1 [52] and, importantly, has neither
binding nor functional activity at GPR55 [36].
Arachidonyl-2′-chloroethylamide (ACEA) and arachidonylcyclo-
propylamide (ACPA), first synthesised in 1999, are both analogues of
AEA and are potent, selective agonists of the CB1 receptor [71]. Both of
these compounds bind CB1 receptors with higher affinity than AEA, and
inhibit forskolin-stimulated adenylyl cyclase activity in cells expressing
the CB1 receptor, but not in cells expressing the CB2 receptor [71].
Rimonabant – SR141716a – is a selective antagonist for CB1 receptors,
able to antagonise the effects of both anandamide and WIN55212, and
is thus a competitive antagonist at the CB1 receptor [52,72]. Rimona-
bant was approved as an antiobesity drug in the EU in 2006, but was
withdrawn from use in the EU in 2008 due to serious psychiatric ad-
verse effects, including suicide. However, SR141716a remains widely
used for research, along with the structurally similar AM251 which acts
as a potent inverse agonist at CB1 receptors, to allow dissection of CB1
and CB2 receptor activity.
First synthesised in 1999, JWH-133 is a THC analogue which is a
highly selective, full agonist for CB2 [73]. Excitingly, this synthetic
cannabinoid has been shown to reduce spasticity in a murine model of
multiple sclerosis [74], thus highlighting the therapeutic potential of
selective synthetic cannabinoids. JWH-015 is also a selective CB2 ago-
nist which is widely used to date for CB2 research [75,53]. In terms of
antagonists, both AM630 and SR144528 are more potent at blocking
CB2 activity over CB1 activity, exhibit higher affinity for CB2, and block
agonist-induced CB2 activation in a competitive manner [67].
The activity of synthetic cannabinoids at GPR55 has yielded some
surprising results. Both the CB2 agonist JWH015 and the CB1 antagonist
AM251 evoke an increase in intracellular calcium in HEK293 cells ex-
pressing GPR55 [76]. Meanwhile, GPR55 is unresponsive to the non-
selective CB agonist WIN55212, yet the CB1 antagonist SR141716a is
also an antagonist at GPR55 [76]. Lastly, some selective synthetic
cannabinoids now exist for GPR55 – ML184 is a potent and selective
agonist at this receptor [34], while ML193 is a potent and selective
antagonist [77].
3. CB1 and CB2 Receptors – the classical cannabinoid receptors
The CB1 receptor, first cloned in 1990 [78], are widely expressed in
the central nervous system within both neurons and glial cells, where
they are predominantly expressed at the terminals of neurons. Here,
they serve as modulators of both excitatory and inhibitory neuro-
transmission, and mediate numerous brain functions including cogni-
tion [79]. Furthermore, CB1 activity protects against excitotoxicity and
promotes repair mechanisms in response to neuronal damage [41].
Cloning of the CB2 receptor followed soon after in 1993 [70]. Its
expression is classically associated with the periphery where it is largely
implicated in immune functions [80], and is responsible for the anti-
inflammatory effects of cannabis [81]. In peripheral immune cells, such
as B lymphocytes, natural killer cells, monocytes, macrophages, mi-
croglia and T lymphocytes [80], CB2 is thought to modulate cell mi-
gration and cytokine release. CB2 is also found on microglial cells – the
resident immune cells of the brain [82] – yet is barely detectable in the
healthy brain [83]. However, evidence for neuronal CB2 expression in
the hippocampus, and a resulting role in synaptic plasticity, has re-
cently been described [81]. Furthermore, CB2 levels in the brain have
been shown to be elevated in response to neuroinflammation and CNS
damage, indicating a far more prominent role for CB2 in the CNS than
originally believed (see discussion below).
Both CB1 and CB2 signal predominantly through Gαi/o proteins, and
thus in a manner similar to M2 and M4 mAChRs, inhibit adenylyl cy-
clase but have also been reported to increase activation of the MAPK
pathway [41], inhibit voltage-dependent Ca2+ channels, and activate
K+ channels [41]. Therefore, the predominant role of endocannabinoid
receptors is to modulate cell excitability.
3.1. CB1 and CB2 are promiscuous GPCRs capable of oligomerisation
Although the majority of work on CB1 and CB2 receptors has fo-
cussed on their coupling to Gαi/o, both of these endocannabinoid re-
ceptors are now understood to be among the GPCRs capable of coupling
to numerous G proteins in a manner often described as promiscuous
coupling. For example, CB1 is proposed to heteromerise with the do-
pamine receptor type 2 long form (D2L), the μ-, κ-, and δ-opioid re-
ceptors, the orexin-1 receptor, the A2A adenosine receptor (A2A) and the
β2 adrenergic receptor (β2-AR) [84–90]. Importantly, CB receptor
coupling to alternative pathways appears to be particularly prevalent in
the case of oligomer formation [91]. Such alternative pathways can also
be unmasked with the blockade of the Gαi pathway with pertussis toxin
(PTX), or can be dependent on the CB1 agonist used [91].
The most widely documented incidence of CB receptor promiscuity
is CB1 coupling to Gαs proteins [91–93], by which adenylyl cyclase is
activated and cAMP response element binding (CREB) protein becomes
phosphorylated [94]. As activation of GPCRs coupled to Gαi/o – such as
CB1 and CB2 receptors – results in the inhibition of adenylyl cyclase and
a subsequent decrease in cAMP levels, the activation of GPCRs coupled
to Gαs therefore initiates an almost opposite cellular response to that
which is typically associated with CB1 and CB2 receptors. The Gαs
phenotype was first seen upon co-stimulation of primary rat striatal
neuronal cultures, and upon Gαi/o inhibition in CHO cells expressing
human CB1 (CHO-hCB1) [92]. When stimulated with either quinpirole
(a D2 receptor agonist) or HU210 (a CB1 receptor agonist) alone, for-
skolin-induced cAMP was inhibited in striatal neurons in a typical Gαi/
o-mediated response. However, co-stimulation with both quinpirole and
HU210 reversed this inhibitory response, resulting in an augmented
cAMP accumulation in a dose-dependent manner, indicating that CB1-
D2 oligomers signal through Gαs [92]. Meanwhile, this same study
demonstrated that stimulation of CHO-hCB1 cells with HU210 resulted
in a dose-dependent cAMP inhibition, yet blockade of Gαi/o with PTX
resulted in a dose-dependent cAMP accumulation in the absence of
either quinpirole co-stimulation or indeed the D2 receptor, thus in-
dicating that the CB1 receptor alone is sufficient to induce a non-Gαi/o
signalling profile [92]. A more recent study has indicated that com-
bined D2 antagonism with haloperidol and CB1 agonism with ACEA in
CB1-D2L heteromers in STHdhQ7/Q7 not only enhances CB1 coupling to
Gαs, but haloperidol in fact behaves as an allosteric modulator of CB1
coupling the Gαs [95]. It has been hypothesised that the physiological
relevance of such a functional switch is to provide discrete regulation of
neurotransmitter signals [92].
Coupling of the CB1 receptor to Gαq [96,97] has also been reported,
with a physiological role for Gαq-coupled CB1 having been suggested in
the induction of autaptic long term depression (autLTD). In primary
hippocampal neuronal cultures, autLTD can be induced with an
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intermittent low-frequency stimulus. However, autLTD was strongly
diminished when 2-AG production was blocked with a DAG lipase in-
hibitor, reversed when neurons were treated with the CB1-selective
antagonist SR141716, and absent altogether in primary hippocampal
neuronal cultures from CB1−/− mice [97]. However, autLTD induction
could not be prevented with the treatment of pertussis toxin and thus
blockade of Gi/o [97]. Indeed, the induction of LTD is dependent on the
presynaptic accumulation of PLC and filled Ca2+ stores, consistent with
Gαq coupling. While autLTD remains poorly understood in relation to
other forms of synaptic plasticity and depression, this study also in-
dicated that autLTD was dependent on either ionotropic or Group I
metabotropic glutamate receptors. The authors thus concluded that the
activation of the CB1 receptor and subsequent coupling to Gαq confers
the release of presynaptic glutamate [97].
Lastly, CB1 coupling to Gαz has been implicated in cross-tolerance
with the μ-opioid receptor arising from receptor desensitisation by
regulation of adenylyl cyclase activity and the gating of certain K+
channels [98]. The CB1 receptor co-precipitated with histidine triad
nucleotide binding protein 1 (HINT1) – a signalling motif associated
with Gαz coupling in the μ-opioid receptor – in the periaqueductal grey
matter of mice. CB1 receptor association with HINT1 was further in-
creased following WIN55212, although in mice where Gαz protein le-
vels had been decreased with oligodeoxynucleotides directed against
Gαz, no WIN55212 desensitisation was seen [98]. Increased association
with HINT1 was not seen following THC administration, indicating that
only exposure to certain cannabinoids results in increased coupling to
Gαz and thus desensitisation [98]. The authors of this study therefore
hypothesised that certain cannabinoids may determine a G protein bias
upon ligand binding, a phenomenon which could therefore be of ther-
apeutic use, as the choice of ligand could dictate G protein coupling and
thus functional outcome.
CB receptor G protein promiscuity has also been observed in CB2
receptor coupling to Gαs [99,100], which has recently been implicated
in wound healing in the cornea [101]. However, there is a surprising
paucity of data on this matter relative to that surrounding G protein
promiscuity at CB1, indicating the need for further research in this field.
Both the cannabinoid agonist used and the expression level of Gαi
have been recently shown as crucial to the switch in G protein coupling
in cannabinoid receptors [91]. Indeed, the functional switch from Gαi
to Gαs coupling was reversible by both pharmacological knockdown
with an irreversible CB1 antagonist (AM6544) and by increasing Gαi
expression levels [91]. Collectively, this has led to the hypothesis that
alternative signalling pathways are initiated upon Gαi exhaustion, due
either to Gαi inactivation or sequestration by another receptor such as
the D2 dopamine receptor [91,95]. The dependency of G protein cou-
pling on the choice of ligand indicates that, akin to many GPCRs,
pathway bias in CB receptors may be therapeutically useful when tar-
geting specific, disease-related pathways. The phenomenon of CB re-
ceptor promiscuity raises the possibility of the activation of different
pathways in different physiological contexts, and highlights a far
greater level of complexity in endocannabinoid signalling than was
originally realised when CB1 and CB2 were first cloned in the early
1990s.
3.2. GPR55 – a recently deorphanised, third cannabinoid receptor
GPR55 has functions in both the periphery and the CNS. In the
periphery, GPR55 is expressed in the adrenal glands, endothelial cells
and the gastrointestinal (GI) tract [36,76,102]. Surprisingly, evidence
has been found for both pro- and anti-inflammatory effects of GPR55 in
the periphery. LPI produced by macrophages is increased during in-
flammatory conditions [103], while LPI and AM251 (an agonist at
GPR55) induce a directional migration of human peripheral blood
neutrophils [104], and activation of GPR55 increases pro-inflammatory
cytokine release from monocytes and natural killer cells [105–107]. On
the other hand, GPR55 has also been found to attenuate
neuroinflammation and chronic pain in a dinitrobenzenesulfonic acid-
induced colitis model [108,109]. It is therefore likely that the role of
GPR55 is dependent upon physiological context and inflammatory
conditions.
In the CNS, GPR55 is found in several regions of the brain, the
caudate nucleus, putamen, hippocampus, thalamus, pons, cerebellum,
frontal cortex and hypothalamus [36,102]. GPR55 has also been re-
ported to be located on neural stem cells, where it is proposed to have
functions in neural stem cell proliferation, neuronal survival, neuronal
differentiation [30] and the regulation of growth cone morphology
[110]. Of note, recent evidence indicates that GPR55 activation in the
hippocampus can boost glutamate release and modulate synaptic
plasticity in the CA1 region [111,112].
In contrast to CB1 and CB2 receptors, GPR55 is coupled to Gα12/13
[32,36,113] and Gαq proteins [76,114–117]. Activation of GPR55
therefore results in the activation of RhoA/Rho-associated protein
protein kinase (ROCK), protein kinase B (Akt), and PLC pathways thus
increasing neuronal excitability [33,76,118,119]. Much like the pro-
miscuity of CB1, it is believed that GPR55 G-protein coupling is con-
ferred by the ligand of choice [33]. It is still unclear which G protein is
preferred by GPR55; both mice doubly deficient in Gαq and Gα11 in
nociceptive neurons (SNS-Gαq/11−/−) and those deficient in Gα13
(SNS-Gα13−/−) in nociceptive neurons showed a partial but significant
reduction in LPI-induced hypersensitivity, indicating that both Gαq/11
and Gα13 contribute to LPI-induced hypersensitivity in the same phy-
siological context i.e. nociceptive neurons of the DRG [120]. However,
it remains plausible that, akin to CB promiscuity, G protein coupling of
GPR55 could be dependent on physiological context. Indeed, much
early work on GPR55 was carried out in HEK293 cells [32,36,76]; this
therefore limits the conclusions which can be drawn about preferential
G protein coupling in vivo.
4. The endocannabinoid system in Alzheimer's disease
The endocannabinoid system is one of many neurotransmitter sys-
tems affected by Alzheimer's disease. Alterations in CB1 receptor ex-
pression and functionality have been described in both AD animal
models [121,122] and the brains of AD patients [123–125]. Interest-
ingly, these alterations vary throughout the progression of AD. In the
early stages of disease, both human AD patients and AD animal models
exhibit an increase in CB1 activity and expression [122,125], perhaps as
a neuroprotective response [126]. In contrast, late-stage AD is asso-
ciated with a reduction of CB1 expression [123] in numerous brain
regions including the CA3 and CA1 regions of the hippocampus
[127,129].
Postmortem brains of AD patients have indicated that levels of
MAGL and FAAH – the breakdown enzymes for 2-AG and anadamide,
respectively – are upregulated [131]. Therefore, the early-stage in-
crease in CB1 expression may be in part attributed to a concomitant
upregulation of these enzymes and thus overall reduction in en-
docannabinoid availability. Upregulation of 2-AG via genetic deletion
of MAGL in mice surprisingly enhanced LTP, object recognition and
spatial memory, with a significantly decreased CB1 receptor binding
density [128]. Pan et al. proposed that genetically enhanced 2-AG le-
vels resulted in tonic activation and consequential desensitisation of the
CB1 receptor [128]. It is thus plausible that AD-related upregulation of
MAGL – initiating a downregulation of 2-AG availability – results in a
compensatory upregulation of CB1 receptors and is therefore re-
sponsible for the increase in CB1 receptor density seen in the initial
stages of AD.
Although CB2 receptor expression levels are relatively low in the
healthy brain [83], expression of this receptor is upregulated in amy-
loid-associated neuroinflammation, seen in both human AD patients
and rats inoculated with β-amyloid [123]. This has been illustrated in
mice expressing five familial Alzheimer's disease mutations (5xFAD
mouse model) with enhanced green fluorescent protein (EGFP) tagged
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CB2 receptor, which showed enhanced EGFP – and thus CB2R – ex-
pression at 3months [129]. This 3month point represents a point
which precedes the onset of cognitive symptoms and deterioration of
synaptic transmission in this mouse model, evident at around 6months.
EGFP-CB2R labelling was detected specifically in areas of intense in-
flammation and amyloid deposition and was coincident with the ap-
pearance of plaques in the cortex, hippocampus, brain stem and tha-
lamus [129]. Furthermore, EGFP expression was restricted to activated
microglial cells surrounding neuritic plaques, and was remarkably ab-
sent in non-plaque regions, indicating that the upregulation of CB2R is
directly related to plaque development. This is consistent with ob-
servations from postmortem human tissue from patients with neuro-
degenerative disorders accompanied by inflammation, including AD
[129]. It is not yet clear whether the upregulation of CB2 is a cause or
effect of neuritic plaque formation, although it has been suggested that
CB2 is induced under neuroinflammatory conditions [129]. Further-
more, given that the first incidence of CB2R upregulation in the 5xFAD
mouse model correlates with amyloid deposit at 3 months, Lopez et al.
[129] hypothesised that the induction of CB2 receptor expression in the
CNS takes place after a period of sustained neuroinflammation, and
even postulated that CB2 receptor expression in the CNS could be an
early indicator of AD [129]. Given that CB2 receptor upregulation in the
CNS precedes phenotypic symptoms of AD, this receptor could re-
present an early target for AD [129].
The endocannabinoid system is thus an attractive target system in
AD, particularly in the early stages. Given that many AD symptoms
arise from cholinergic dysfunction, and are paralleled with changes in
the endocannabinoid system, there is therefore potential for crosstalk
between the endocannabinoid and muscarinic systems. In particular,
disease-related changes in endocannabinoid function may offer ther-
apeutic possibilities in AD.
5. Crosstalk between muscarinic and endocannabinoid receptors –
implications for Alzheimer's disease
Crosstalk has been described between both the nAChRs and
mAChRs with the endocannabinoid system. Although α7 nAChR
agonism with PNU282987 has been shown to be unaffected by both CB1
antagonism with rimonabant and CB2 antagonism with SR144528
[130], the α5 and α6 nAChRs have been recently implicated in THC
dependency and withdrawal [131]. Therefore, although nAChR cross-
talk with the endocannabinoid system may not be directly related to
AD, this highlights the potential for the cannabinoid system to influence
global cholinergic signalling and is thus a crucial consideration in the
use of cannabinoids to target the cholinergic system in AD.
The crosstalk between CB1 and muscarinic receptors in AD has been
recently investigated using the triple transgenic mouse model of AD –
the 3xTg-AD model – in which mice are homozygous for the PSEN1
(presenilin-1) mutation, APP (amyloid precursor protein) Swe trans-
gene, and tauP301L transgene. 3xTg-AD mice exhibit impaired synaptic
plasticity, which is thought to arise from the dysregulation of hippo-
campal presynaptic muscarinic neurotransmission, thus inhibiting
memory creation and maintenance [132]. In these mice, intraneuronal
Aβ appears at 2–4months alongside impaired mAChR-mediated sig-
nalling [133], with cognitive impairment being accompanied by ele-
vated CB1 expression at around 7months [126,134]. While cognitive
impairment becomes more evident in middle-aged (13–15months)
mice, a simultaneous decrease in choline acetyltransferase and CB1
expression is seen [126,134]. In late life (18–20months), these mice
exhibit hippocampal and cortical cholinergic neuritic dystrophy, par-
alleled with the progression of amyloid-α plaque formation [132].
These changes in both mAChR and CB1 expression and function are
parallel to those seen in human AD as discussed above. Indeed, a po-
sitive and statistically significant correlation was found between CB1
receptor density in the basolateral amygdala and acquisition latencies
in 3xTg-AD mice, indicating that changes in CB1 density may contribute
to deficits in acquisition [132]. In the 3xTg-AD mouse model, therefore,
CB1 expression may influence cognitive function.
The elevated CB1 expression observed in 7-month-old 3xTg-AD mice
may represent a therapeutic window. By stimulating the CB1 receptor
with the synthetic agonist WIN55212, disease-associated acquisition
latencies were reversed at this time point in 3xTg-AD mice to levels
comparable with non-Tg control mice [132]. Furthermore, WIN55212
reversed disease-associated impairments in functional coupling of M2/
M4 mAChRs to Gi/o proteins in the basolateral amygdala, lateral
amygdala and hippocampal CA1 region [132]. Therefore, by both di-
rectly activating the CB1 receptor through agonist administration,
Llorento-Ovejero et al. [132] reversed both cognitive and functional
cholinergic deficits in 3xTg-AD mice. In the 5xFAD model, mice over-
express mutant human APP(695), while also expressing the Swedish,
Floridian and London Familial AD mutations, in addition to two FAD
mutations M146L and L286V, both of which become overexpressed in
the brain due to their regulation by the mouse Thy1 promoter. In
contrast to the 3xTg-AD model, blockade of CB1 with SR141716 – a
CB1-specific antagonist – exacerbated neuroinflammation in the 5xFAD
mouse model [135]. Despite exacerbating neuroinflammation, antago-
nist treatment of the CB1 receptor neither attenuated nor exacerbated
spatial memory in 5xFAD mice [135]. Meanwhile, the genetic deletion
of CB1 has been shown to create an imbalance of excitatory/inhibitory
neurotransmission in the hippocampus, drastically accelerating
memory impairment and reducing survival in APP/PS1 transgenic
mice. The APP/PS1 mouse model is a double transgenic mouse model,
expressing a chimeric mouse/human amyloid precursor protein, and a
mutant human presenilin 1(PS1-dE9), and represents a model of fa-
milial AD with cognitive impairments, Aβ plaque deposition and sy-
naptic abnormalities from 6months of age [138]. The effects of acti-
vating, blocking, or deleting the CB1 receptor in mouse models of AD
therefore highlight the importance of CB1 in the modulation of AD-like
symptoms, particularly those attributed to cholinergic dysfunction.
Importantly, activation of the CB1 receptor in vulnerable limbic areas
via a CB receptor agonist is capable of reversing symptoms of choli-
nergic deficit and reversing functional mAChR impairments, while
blockade or genetic deletion of the CB1 receptor can exacerbate disease.
Collectively, this indicates that the early upregulation of CB1 expression
in AD may serve a pivotal, and druggable, role in an attempt to protect
cholinergic function via CB1-mediated pathways.
While direct activation of CB1 has shown promising effects, en-
hancing synaptic endocannabinoid availability through blockade of
MAGL and FAAH has yielded mixed results. The pharmacological in-
hibition of MAGL – thus increasing synaptic availability of 2-AG – with
JZL-184 showed the same reversal of acquisition latencies seen in 7-
month 3xTg-AD mice as CB1 activation with WIN55212 [132], and
improvements in spatial learning and memory with simultaneous re-
pressed β-amyloid accumulation in 5xFAD mice [136]. However, unlike
agonist treatment, JZL-184 had no improvement on functional M2/M4
mAChR coupling in 3xTg-AD mice [132]. Meanwhile, pharmacological
inhibition of FAAH had little effect on cognitive impairment, plaque
deposition or inflammatory markers in 5xFAD mice [135], indicating
that the pharmacological enhancement of anandamide levels – in con-
trast to 2-AG enhancement – does little to improve symptoms of AD in
this particular mouse model. On the other hand, FAAH-null 5xFAD mice
showed a behavioural improvement in spatial memory tasks and di-
minished levels of both soluble amyloid and neuritic plaque density
[135], indicating that perhaps a lifelong upregulation of anandamide
availability is protective against the onset of AD-like symptoms in
5xFAD mice. Surprisingly, a paradoxical elevation of pro-inflammatory
cytokines levels was also seen in these mice, and the attenuation of
memory impairment was not reversed by administration of SR141716 –
a CB1 antagonist – indicating that genetically elevated anandamide
levels do not mediate improvements in spatial memory via CB1 [135].
Given that anandamide also activates GPR55 and CB2, it is possible that
genetic deletion of FAAH leads to anandamide acting not only on CB1,
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but instead on the endocannabinoid system as a whole, to improve
cognitive function and attenuate the onset of markers of AD. Indeed, as
discussed above, the activation of GPR55 leads to the release of gluta-
mate and thus supports LTP formation [111,112]. Furthermore, ana-
ndamide has been shown to bind to M1 and M4 mAChRs, where it is
thought to bind to allosteric sites [137,138]. It is therefore possible that
the CB1-independent properties of genetic FAAH ablation could, in part,
be explained by activation of GPR55, CB2 or even binding to non-CB
receptors such as the mAChRs.
As discussed above, upregulated CB2 receptor expression in the CNS
has been recently implicated in the development of neuroinflammation,
and as such could be a target for the treatment of AD. Indeed, genetic
deletion of CB2 in 5xFAD mice (CB2R−/− /5xFAD) showed a small but
significant decrease in hippocampal neuritic plaque density [129].
However, these mice did not show any changes in Aβ1–42 levels or
reduced microgliosis in comparison to their wildtype littermates [129].
Meanwhile, deletion of CB2 in APP/PS1 mice resulted in an improve-
ment of cognitive and learning deficits with a concomitant reduction in
neuronal loss, decreased plaque levels and increased expression of Aβ
degrading enzymes [139]. In contrast, however, the pharmacological
activation of the CB2 receptor via the CB2-selective agonist JWH-133
may also be beneficial in neurodegeneration. In an okadaic acid rat
model of AD, neurodegeneration, neuroinflammation, Aβ accumulation
and impairment of cognitive function were all prevented following
daily administration of JWH-133 over a two-week period [140]. Re-
ductions in pathological hallmarks of disease were accompanied by a
reversal of spatial memory impairment and anxiety to control levels
[140]. Therefore, the precise role of CB2 in neurodegenerative disease
remains unclear, although these data collectively indicate that targeting
the CB2 receptor could prevent or reverse the formation of neuritic
plaques and, importantly, reverse memory impairments in AD.
6. Cannabinoids modulate the M1 mAChR in pilocarpine-induced
seizure
In addition to its role in learning and memory, the M1 mAChR has
long been implicated in the mediation of seizure onset. While genetic
disruption of M1 ablates seizure activity in mice [141], both inhibition
of AChE by organophosphorous (OP) compounds [142,143] and treat-
ment with pilocarpine induce seizures in rodents [144]. The latter
shows a phenotype similar to human temporal lobe epilepsy, and is thus
a widely used model of this disease state [144]. These effects are long-
lasting, with pilocarpine-treated animals developing spontaneous sei-
zures a few weeks after compound administration. Consistent with the
notion that the spontaneous seizures in this model is driven by mAChRs
is the fact that pre-treatment with muscarinic antagonists prior to pi-
locarpine treatment can block the development of spontaneous sei-
zures. However, muscarinic antagonist administration after pilocarpine
treatment does not terminate seizure activity. Therefore, mAChRs are
required for the development, but not necessarily the maintenance of
pilocarpine-induced spontaneous seizures [144].
The effectiveness of directly targeting CB1 in seizure states can be
illustrated by both CB1 knockout mouse models and CB1 antagonist
administration, both of which increase pilocarpine seizure sensitivity in
the pilocarpine-induced seizure model [144]. However, this is not re-
stricted to this particular seizure model, as CB1 ablation and antagonist
treatment both produce proconvulsive phenotypes in electroshock,
spontaneous and kainic acid seizure models of epilepsy [145–148]. On
the other hand, both endocannabinoids and CB1 receptor agonist ad-
ministration can attenuate seizures in all of these models. Collectively,
this is indicative that constitutive CB1 activity via endocannabinoids
modulates not only mAChR-driven seizure activity, but also the onset of
seizures through other neurotransmitter systems, which is reflective of
the fact that the endocannabinoid system is indeed a modulatory
system for a breadth of neurotransmitters. A protective role for CB1 has
been described in the OP-induced seizure model, whereby CB1
antagonism with AM251 significantly increased mortality in mice
[149]. Given that OP-induced seizures are mediated by inhibition of
AChE – and thus an augmentation of synaptic acetylcholine – this
therefore indicates that presynaptic CB1 receptors play a crucial role in
the attenuation of presynaptic acetylcholine release. However, the
agonism of CB1 as an approach to the treatment of seizures must be
approached with caution, as a maximal dentate activation model of
limbic seizures in anaesthetised rats indicated that direct CB1 agonism
with WIN55212 resulted in impairments of LTP in addition to seizure
attenuation [150]. The same study found that FAAH inhibition with
URB597 inhibited seizure in a CB1-dependent manner, while avoiding
the deleterious effects seen with WIN55212 [150]. Therefore, while
targeting CB1 in seizure models shows therapeutic promise, it may also
result in adverse effects. Meanwhile, enhancing endocannabinoid tone
appears to result in the same anticonvulsant improvements while
avoiding deleterious effects of CB1 agonism. Of great importance,
however, is that these studies highlight the involvement and protective
nature of CB1 in the modulation of seizures driven by mAChR over-
stimulation, and the therapeutic potential for targeting the en-
docannabinoid system in disorders of cholinergic dysfunction.
Given that the World Health Organisation states that epilepsy con-
tinues to affect some 50 million individuals worldwide, the attenuation
of seizures via both phyto- and synthetic cannabinoids highlights the
enormous potential for further defining the endocannabinoid system as
a target for seizures. Anecdotal reports arising from the recent growth
of public interest in the use of cannabinoids particularly emphasise the
effectiveness of CBD over THC. Indeed, recent placebo-controlled trials
have shown that the daily addition of 20mg per kg of bodyweight of
CBD to antiepileptic medication in Dravet syndrome resulted in a re-
duction in convulsive-seizure of at least 50% in 43% of participants
[151], while reducing the frequency of drop seizures in Lennox-Gastaut
syndrome by 41.9% [152]. The effectiveness and popularity of CBD
over may be reflected in the differing pharmacology whereby, as dis-
cussed earlier, THC is a partial agonist at CB1 and CB2, while CBD is a
NAM at CB1, a partial agonist at CB2 and an inhibitor of anandamide
uptake. Adding yet further complexity to the role of cannabinoids in
seizure modulation, THC may also be a competitive inhibitor of AChE in
vitro [153], thus implying that THC could actually enhance synaptic
acetylcholine levels, which would be deleterious in ACh-driven sei-
zures. Therefore, the somewhat complex pharmacological properties of
CBD – including blockade of anandamide uptake – may combine to
attribute anticonvulsant effects, while direct agonism at CB1 – as seen
with THC – may be associated with more adverse effects. Therefore,
while the phyto- and synthetic cannabinoids show great promise in the
treatment and prevention of seizures, more research is required to
elucidate the precise role of the endocannabinoid system, particularly
with regards to its role in crosstalk with the muscarinic receptors in
disease states, prior to the exploitation of cannabinoids for therapeutic
benefit.
7. Concluding remarks
The endocannabinoid system is a relatively new research field, the
true therapeutic potential of which has not yet been fully elucidated.
While many efforts in AD research strive to directly target the mAChRs
through either orthosteric or allosteric compounds, emerging evidence
indicates that, as modulatory receptors, endocannabinoid receptor
crosstalk with mAChRs may serve as a way to indirectly fine tune
cholinergic dysregulation. This may be of particular importance during
discrete disease stages, such as during the upregulation of CB1 in the
early stages of Alzheimer's disease. However, targeting the en-
docannabinoid system is not without its challenges, as CB1 is the most
abundantly expressed GPCR in the CNS and the principal regulator of
neuronal function with diverse effects on neuronal responses [149].
Therefore, a deeper understanding around the specific roles of these
receptors on discrete neuronal populations, and strategies for directly
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targeting cannabinoid receptors in areas of the CNS relevant to disease
are required before the endocannabinoid can be fully exploited as a
drug target. Meanwhile, public perception around the recreational use
of cannabinoids and the harmful nature of prolonged cannabis-based
drug abuse has hampered the commitment of the scientific community
to test the notion of the endocannabinoid system as a legitimate target
in certain disease settings. Collectively, this highlights the continued
need for research to be aimed towards deepening our understanding of
the endocannabinoid system to optimise drug design for these emerging
targets, and their role in disorders of cholinergic dysfunction such as
seizure induction and AD.
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